A noninvasive device used to treat nonmelanoma skin cancers with radiation is getting a $2.4 million boost from investors as it makes its way into more oncology centers and dermatology offices across the world.
In a recent U.S. Securities and Exchange Commission filing, Sensus Healthcare LLC reported raising $2.4 million from 19 investors. The company’s media representative couldn’t be reached for more details.
Sensus markets a superficial radiation therapy (SRT) system to treat basal cell and squamous cell carcinomas, the most common forms of skin cancer. The SRT-100 delivers targeted, low-energy radiotherapy no deeper than the thickness of the skin.
Traditionally, to treat nonmelanoma cancers, a procedure called Mohs surgery is performed, where the physician removes the tumor with a thin layer of tissue around it. Sensus says SRT doesn’t require anesthesia, is painless and avoids tissue damage and scarring, which results in a shorter healing time. Unlike a surgical procedure, multiple treatments are required, although each one takes only a few minutes.
Sensus was formed in 2010 in Boca Raton, Florida and acquired SRT-100 from Topex Inc. later that year. The device was featured on the show “The Doctors” in early 2012 and saw its 100th sale in September. It’s cleared for sale in the U.S., EU, Canada and China.
The Skin Cancer Foundation estimates that 2.8 million new cases of basal cell carcinoma are diagnosed each year in the U.S. Although surgery is the standard, patients who aren’t well-suited for surgery may use cryotherapy, laser surgery or topical drug treatments. Galena Biopharma, Spectrum Pharmaceuticals and Exelixis are among those developing new drug treatments.
[Screen cap from Sensus Healthcare]
Reserve your seat now for MedCity CONVERGE, to be held July 9-10 in Philadelphia. Discover strategies, solutions and startups in healthcare innovation. Be a part of this gathering where the entire healthcare ecosystem converges.